Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) CEO Robert Berman tells Proactive Investors the medical-devices developer is looking forward to preliminary data results on the first group of patients treated with the company's VenoValve in June 2019. Berman says VenoValve is surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, a disease that affects 2.4 million in the US, and a disease from which one of the company's directors recently passed away.
0 Comments